New drug cocktail aims to tame rare lung cancer
NCT ID NCT07561645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Researchers will measure how long patients live and how well the cancer responds to treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo targets rare, aggressive lung cancer
- Triple-Drug cocktail takes aim at rare, aggressive cancers
- Engineered immune cells take aim at tough lung cancer
- Radioactive drug targets tough lung cancers in early trial
- New hope for Chemo-Resistant lung cancers?
- Immunotherapy plus chemo shows promise for rare lung cancer